{
    "clinical_study": {
        "@rank": "87491", 
        "brief_summary": {
            "textblock": "Emergency access granted to treat a single patient with advanced Mucopolysaccharidosis Type\n      7 with UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy via IV\n      administration every other week (QOW) for 48 weeks."
        }, 
        "brief_title": "An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient", 
        "condition": "Mucopolysaccharidosis Type 7", 
        "condition_browse": {
            "mesh_term": "Mucopolysaccharidoses"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1 specific patient\n\n          -  Confirmed diagnosis of MPS 7 based on leukocyte or fibroblast glucuronidase enzyme\n             assay or genetic testing confirming diagnosis.\n\n          -  Written informed consent of parent(s) or legal guardian(s)"
            }, 
            "gender": "Male", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "id_info": {
            "nct_id": "NCT02097251", 
            "org_study_id": "13-606A"
        }, 
        "intervention": {
            "description": "Open Label", 
            "intervention_name": "UX003", 
            "intervention_type": "Drug", 
            "other_name": [
                "recombinant human beta glucuronidase", 
                "rhGUS"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Mucopolysaccharidosis Type 7", 
            "Sly syndrome", 
            "UX003", 
            "Enzyme Replacement Therapy", 
            "rare disease", 
            "Lysosomal Storage Disease", 
            "metabolic disorder"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Hyde Park", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11040"
                }, 
                "name": "Cohen Children's Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label Treatment Protocol With UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy for an Advanced Stage Mucopolysaccharidosis Type 7 (MPS 7) Patient", 
        "overall_status": "Temporarily not available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097251"
        }, 
        "responsible_party": {
            "investigator_affiliation": "North Shore Long Island Jewish Health System", 
            "investigator_full_name": "Joyce Fox", 
            "investigator_title": "Chief of Medical Genetics at Cohen Children's Medical Center", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "North Shore Long Island Jewish Health System", 
        "sponsors": {
            "collaborator": {
                "agency": "Ultragenyx Pharmaceutical Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Joyce Fox", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "March 2014"
    }
}